ArticleGynecologic oncology reports2021
Uterine mesenchymal tumors harboring
Article in Gynecologic oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib.Gynecologic oncology reports · 2026Article
- Article
- Review
- Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboringFrontiers in oncology · 2026Article
- Uterine leiomyoma-like inflammatory myofibroblastic tumor: two case reports and literature review.Frontiers in oncology · 2026Article
- The Evolving Molecular Landscape of Uterine Mesenchymal Tumors: Diagnostic and Therapeutic Implications.Cancers · 2025Review
- Alectinib as salvage therapy for metastatic UIMT following misdiagnosis: A case enabling definitive surgery and prolonged remission.Gynecologic oncology reports · 2025Article
- Uterine leiomyoma-like inflammatory myofibroblastic tumour with a rare ALK::SYN3 fusion: a clinicopathologic and molecular analysis.Diagnostic pathology · 2025Review
- Inflammatory Myofibroblastic Tumor: An Updated Review.Cancers · 2025Review
- The clinicopathologic features of uterine inflammatory myofibroblastic tumor: A case report.Medicine · 2025Article
- Case Report:Frontiers in oncology · 2025Article
- Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion.Frontiers in oncology · 2025Article
- Emerging Tumor-Agnostic Molecular Targets.Molecular cancer therapeutics · 2024Review
- A bibliometric analysis of literatures on uterine leiomyosarcoma in the last 20 years.Frontiers in oncology · 2024Article
- Update of Diagnosis and Targeted Therapy for ALKCurrent treatment options in oncology · 2023Review
- Targeted Treatment of Soft-Tissue Sarcoma.Journal of personalized medicine · 2023Review
- Fertility-preserving management of an inflammatory myofibroblastic tumor: A case report and review of the literature.Case reports in women's health · 2023Article
- Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.Gynecologic oncology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammatory myofibroblastic tumor (IMT) of the uterus is a rare but aggressive malignancy that is often misdiagnosed. Approximately 50% of uterine IMTs (UMT) harbor rearrangements involving the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.